Neoadjuvant Radiotherapy Combined With NALIRIFOX and Adebrelimab in pMMR/MSS Locally Advanced Rectal Cancer: A Prospective, Randomized, Phase II Clinical Trial

Neoadjuvant Radiotherapy Combined With NALIRIFOX and Adebrelimab in pMMR/MSS Locally Advanced Rectal Cancer: A Prospective, Randomized, Phase II Clinical Trial is a phase 2, randomised interventional study registered as NCT07622771 by Sun Yat-sen University, with a registry enrolment figure of 84 participants, started 2026-05-26 and due to reach its primary completion in 2028-06-30. Interventions recorded: Adalimumab+NALIRIFOX→Short course radiotherapy →Adalimumab+NALIRIFOX; Adalimumab+NALIRIFOX→Long course chemoradiotherapy →Adalimumab+NALIRIFOX. Conditions listed: Rectal Cancers. Primary outcome: CR rate. Colorectal eligibility wording from the registry: "Locally advanced rectal adenocarcinoma confirmed by histopathology;". Sites: China. No results are recorded here; the registry entry is the source.